欧洲精品一区二区三区_欧美性性性性_国产一区二区免费在线播放_日日噜噜噜噜人人爽日本精品_无套中出丰满人妻无码_国产偷窥熟女精品视频大全

美國MedImmune
MedImmune公司1988年成立于美國馬里蘭州的Gaithersburg，是一家開發生產抗感染藥物，抗腫瘤藥物和免疫調節藥物的生物技術公司。公司總部位于馬里蘭州的Gaithersburg，在Frederick，Maryland和荷蘭的Ni jmegen有生產廠房，在賓夕凡尼亞州的West Conshohocken有腫瘤學方面的子公司。1999年MedImmune公司兼并了美國Bioscience。公司在納斯達克的股票代碼為MEDI。


In the world of biologics, MedImmune has established itself as a true visionary, with one of the most robust pipelines in the biopharmaceutical industry. From groundbreaking research and development, to state-of-the-art manufacturing, to product commercialization, every day we're touching lives. We're proudly united by the spirit of innovation, the heart of inspiration, and the strength of integration, as we advance science for better health.

The value of health. The promise of Biotech. The purpose of MedImmune.

Spirit of Innovation
Renowned for originality and creativity, and backed by a 20-year heritage, MedImmune is synonymous with intelligent risk-taking and accountability. We strive to address unmet medical needs by developing novel proprietary products and cutting-edge technologies. By incorporating translational sciences, otherwise known as "customized medicine," in an increasing number of our clinical programs, MedImmune is continually striving toward the future.

Heart of Inspiration
Today's MedImmune offers a promising future. Our more than 3,000 employees are dedicated to helping people live better lives. We are developing new therapeutic and preventive medicines that hold tremendous potential for patients around the globe in the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. We're committed to making a difference in science, in the lives of patients, and in the communities in which we operate.

Strength of Integration
With locations in the United States, the United Kingdom, and the Netherlands, we all work together toward one goal: helping people live healthier, longer, and more satisfying lives. Established in 2007 as the global biologics business for AstraZeneca, we have continued to advance our R&D portfolio and expand our headcount, research capability, and manufacturing facilities. We are a catalyst for change, forging ahead with a spirit of collective creativity and expertise.